These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21710471)

  • 1. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.
    Charlton M
    Hepatology; 2011 Jul; 54(1):3-5. PubMed ID: 21710471
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
    Garg V; van Heeswijk R; Lee JE; Alves K; Nadkarni P; Luo X
    Hepatology; 2011 Jul; 54(1):20-7. PubMed ID: 21618566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
    Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy.
    Roos K; Gotthardt D; Giese T; Schnitzler P; Stremmel W; Czock D; Eisenbach C
    Liver Transpl; 2014 Sep; 20(9):1106-17. PubMed ID: 24890314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Boceprevir and telaprevir: clinical efficacy, safety and drug-drug interactions].
    Nikitin AV
    Antibiot Khimioter; 2012; 57(9-10):47-9. PubMed ID: 23477220
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug-drug interaction with telaprevir or boceprevir in liver transplant patients: about four cases].
    Delaborde L; Logerot S; Fonrose X
    Therapie; 2014; 69(6):491-7. PubMed ID: 25320939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boceprevir, telaprevir, and rilpivirine hydrochloride.
    Hussar DA; Snell CW
    J Am Pharm Assoc (2003); 2012; 52(1):120-6. PubMed ID: 22257626
    [No Abstract]   [Full Text] [Related]  

  • 8. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New hepatitis C regimen stimulates changes in therapy management.
    Reinke T
    Manag Care; 2011 Dec; 20(12):41-2. PubMed ID: 22259876
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus.
    Oellerich M; Armstrong VW; Schütz E; Shaw LM
    Clin Biochem; 1998 Jul; 31(5):309-16. PubMed ID: 9721427
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients.
    Kikuchi M; Okuda Y; Ueda Y; Nishioka Y; Uesugi M; Hashimoto E; Takahashi T; Kawai T; Hashi S; Shinke H; Omura T; Yonezawa A; Ito T; Fujimoto Y; Kaido T; Chiba T; Uemoto S; Matsubara K; Masuda S
    Biol Pharm Bull; 2014; 37(3):417-23. PubMed ID: 24369269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors].
    Ruiz Ramos J; Romero Hernández I; Marrero Álvarez P; Marqués Miñana MR; Fernández Megía MJ; Poveda Andrés JL
    Gastroenterol Hepatol; 2014 Dec; 37(10):558-63. PubMed ID: 24951300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New treatments for hepatitis C, which targets, what timeline?].
    Goossens N; Negro F
    Rev Med Suisse; 2011 Sep; 7(307):1683-8. PubMed ID: 21987876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.
    Tischer S; Fontana RJ
    J Hepatol; 2014 Apr; 60(4):872-84. PubMed ID: 24280292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
    Lange CM; Sarrazin C; Zeuzem S
    Pharm Unserer Zeit; 2011 Jan; 40(1):60-7. PubMed ID: 21194084
    [No Abstract]   [Full Text] [Related]  

  • 16. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient.
    Moreau C; Debray D; Loriot MA; Taburet AM; Furlan V
    Transplantation; 2006 Feb; 81(3):487-8. PubMed ID: 16477241
    [No Abstract]   [Full Text] [Related]  

  • 17. Viral hepatitis: Ciclosporin versus tacrolimus for HCV transplant recipients.
    Berenguer M
    Nat Rev Gastroenterol Hepatol; 2011 Jul; 8(8):422-4. PubMed ID: 21750517
    [No Abstract]   [Full Text] [Related]  

  • 18. Tacrolimus/cerivastatin interaction study in liver transplant recipients.
    Mück W; Neal DA; Boix O; Voith B; Hasan R; Alexander GJ
    Br J Clin Pharmacol; 2001 Aug; 52(2):213-5. PubMed ID: 11488782
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.
    Melter M; Rodeck B; Kardorff R; Hoyer PF; Maibücher A; Brodehl J
    Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224
    [No Abstract]   [Full Text] [Related]  

  • 20. [New times for the treatment of chronic hepatitis C].
    Gerstoft J; Fomsgaard A
    Ugeskr Laeger; 2012 Mar; 174(12):795. PubMed ID: 22433552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.